Genexine is a biotechnology company focused on developing long-acting biopharmaceuticals for the treatment of rare diseases and innovative cancer therapies. Operating in the global biotech market, Genexine serves patients with unmet medical needs, particularly those suffering from conditions like anemia, growth hormone deficiency, and HPV-related cancers. The company's business model revolves around leveraging its proprietary long-acting platform technology to create 'bio-better' drugs, which are enhanced versions of existing biologics. Genexine generates revenue through the development, clinical trials, and eventual commercialization of these drugs, often in collaboration with global pharmaceutical companies. Key products in their pipeline include GX E4 for anemia, GX H9 for growth hormone deficiency, and GX 188E, a first-in-class DNA vaccine for HPV-related cancers. The company is also pioneering GX I7, the only long-acting interleukin 7 drug aimed at amplifying T cells for use in combination with immuno-oncology treatments. Genexine's commitment to innovation is further demonstrated by its establishment of a new R&D center in Seoul, designed to foster collaboration and sustainable growth. The company emphasizes a transparent management system and a talent-centered organizational culture to drive its mission of saving lives through groundbreaking medical advancements.

Keywords: biopharmaceuticals, rare diseases, cancer therapies, long-acting drugs, DNA vaccine, immuno-oncology, clinical trials, global biotech, proprietary technology, sustainable growth.